ClinicalTrials.Veeva

Menu

Case Collection Study in the Evaluation of Doubling Time Rates in Non-Suspicious Breast Masses Using QT Ultrasound Technology (EVALUATE)

Q

QT Imaging

Status

Completed

Conditions

Breast Fibroadenoma

Treatments

Diagnostic Test: QT Ultrasound

Study type

Observational

Funder types

Industry

Identifiers

Details and patient eligibility

About

This is a prospective case collection study to collect cases for subsequent statistical studies and future reader studies.

Enrollment

27 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Female
  2. Age 18 or older
  3. Willing to receive QT Ultrasound Breast Scans
  4. Willing to undergo an ultrasound-guided needle breast biopsy if performed after enrollment in the study
  5. Willing and able to provide Informed Consent prior to any research-related procedure(s)
  6. Have an identified solid non-suspicious breast mass

Exclusion criteria

  1. Pregnancy
  2. Currently breastfeeding
  3. Magnetic material in the chest which in the judgement of the Principal Investigator would interfere or be impacted by the magnets utilized with the study device.
  4. Not willing to provide information for primary care physician
  5. History of breast cancer
  6. History of treated or untreated cancer of a non-breast origin which in the judgment of the Principal Investigator would be a concern for metastatic disease to the breast
  7. Physical inability to tolerate the QT scan, i.e. inability to lie prone and still for up to 30 minutes at a time
  8. Open wounds, sores or skin rash present on the breast(s) or nipple discharge from the scanned breast(s)
  9. Breasts too large for scanner, i.e. bra size larger than DDD or inability to successfully "fit" breast after the subject is placed on scanner
  10. Body weight greater than 400 lbs. (180 kg)
  11. Concurrent disease or condition which in the judgment of the Principal Investigator disqualifies the subject from participating in the study

Trial design

27 participants in 2 patient groups

(2) QT Ultrasound scans prior to breast biopsy
Description:
Subjects will undergo a baseline QT scan, and a follow-up QT scan performed between 90 days and 180 days from their baseline QT Scan accompanied by a HHUS and ultrasound-guided breast biopsy following the first follow-up QT scan. BI-RADS will be confirmed by the radiologist at the time of the first HHUS. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for an additional follow-up QT Scan 12 months from the time of their baseline QT Scan.
Treatment:
Diagnostic Test: QT Ultrasound
(0-1) QT Ultrasound scans prior to breast biopsy
Description:
Subjects that have not had (2) two QT Scans before their breast biopsy and who haven't yet had a breast biopsy will undergo an optional baseline QT scan accompanied by a HHUS and ultrasound-guided breast biopsy. BI-RADS will be confirmed by the radiologist. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for a follow-up QT Scan between 90 and 180 days from the time of their study biopsy. Subjects that have had a breast biopsy on their identified breast mass(es) prior to study enrollment and have not already had two (2) QT Scans will undergo an optional baseline QT scan if between 0 and 30 days from their breast biopsy. Subjects will be asked to come back for a follow-up QT Scan 12 months from the time of their study biopsy.
Treatment:
Diagnostic Test: QT Ultrasound

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems